Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp139 | Cancer and bone: basic, translational and clinical | ECTS2013

New PI3Kα-specific inhibitor, BYL719: therapeutic interest in osteosarcoma

Gobin Berengere , Baud'huin Marc , Charrier Celine , Hervouet Soizic , Lezot Frederic , Blanchard Frederic , Heymann Dominique

It has been established that disturbances of intracellular signaling pathways strongly contribute to the oncologic process. Indeed, phosphatidylinositol-3-kinase (PI3K) became a key target in cancer therapy, due to its high frequency of mutation and/or gain of function of its catalytic subunits in cancer cells. In this context, we investigated the in vitro and in vivo effects of a new PI3Kα inhibitor, BYL719 (Novartis Pharma), on bone cells and its thera...

ba0001pp138 | Cancer and bone: basic, translational and clinical | ECTS2013

New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance

Monderer David , Luseau Alexandrine , Bellec Amelie , David Emmanuelle , Ponsolle Stephanie , Saiagh Soraya , Bercegeay Sylvain , Piloquet Philippe , Denis Marc , Lode Laurence , Redini Francoise , Biger Marine , Heymann Dominique , Heymann Marie-Francoise , Bot Ronan Le , Gouin Francois , Blanchard Frederic

Chondrosarcomas are cartilage-forming, poorly vascularized tumors. With an estimated annual incidence of 1 in 200 000, they represent the second malignant primary bone tumor of adults after osteosarcoma. These tumors are resistant to chemotherapy and radiotherapy, surgical excision remaining the only therapeutic option. However, very few cell lines and animal models are available, and the mechanisms behind their chemoresistance remain largely unknown. Our goal was to establish...